HRP20210611T1 - Antitijela selektivna za amiloidne-beta-protofibrile/oligomere krnjih n-terminala - Google Patents
Antitijela selektivna za amiloidne-beta-protofibrile/oligomere krnjih n-terminala Download PDFInfo
- Publication number
- HRP20210611T1 HRP20210611T1 HRP20210611TT HRP20210611T HRP20210611T1 HR P20210611 T1 HRP20210611 T1 HR P20210611T1 HR P20210611T T HRP20210611T T HR P20210611TT HR P20210611 T HRP20210611 T HR P20210611T HR P20210611 T1 HRP20210611 T1 HR P20210611T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- protofibril
- stabilized
- monomer
- binds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22110509P | 2009-06-29 | 2009-06-29 | |
| PCT/IB2010/052947 WO2011001366A1 (en) | 2009-06-29 | 2010-06-29 | N-terminal truncated amyloid beta protofibrils/ oligomers for use in therapeutic and diagnostic methods for alzheimer's disease |
| EP10739701.0A EP2448968B1 (en) | 2009-06-29 | 2010-06-29 | ANTIBODIES SELECTIVE FOR N-TERMINALTRUNCATED AMYLOID-p PROTOFIBRILS/OLIGOMERS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210611T1 true HRP20210611T1 (hr) | 2021-05-28 |
Family
ID=42832352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210611TT HRP20210611T1 (hr) | 2009-06-29 | 2010-06-29 | Antitijela selektivna za amiloidne-beta-protofibrile/oligomere krnjih n-terminala |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20120100129A1 (2) |
| EP (2) | EP3892633A1 (2) |
| JP (3) | JP2012532094A (2) |
| AU (1) | AU2010267640B2 (2) |
| CA (1) | CA2765602C (2) |
| CY (1) | CY1124034T1 (2) |
| DK (1) | DK2448968T3 (2) |
| ES (1) | ES2864049T3 (2) |
| HR (1) | HRP20210611T1 (2) |
| HU (1) | HUE053949T2 (2) |
| LT (1) | LT2448968T (2) |
| PL (1) | PL2448968T3 (2) |
| PT (1) | PT2448968T (2) |
| SI (1) | SI2448968T1 (2) |
| SM (1) | SMT202100237T1 (2) |
| WO (1) | WO2011001366A1 (2) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| RU2429244C2 (ru) | 2006-03-23 | 2011-09-20 | Байоарктик Ньюросайенс Аб | Улучшенные селективные в отношении протофибрилл антитела и их применение |
| CA2789963C (en) | 2010-02-26 | 2019-09-03 | Bioarctic Neuroscience Ab | Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies |
| BR112013023211B1 (pt) | 2011-03-16 | 2022-11-08 | Vivoryon Therapeutics N.V. | Anticorpo monoclonal, seu uso, composição, linhagem celular, método diagnóstico in vitro e kit |
| EP3166970B1 (en) | 2014-07-10 | 2021-03-10 | BioArctic AB | Improved a-beta protofibril binding antibodies |
| US11327080B2 (en) | 2015-07-21 | 2022-05-10 | BioArctic Neruoscience AB | Method for treatment of traumatic brain injury targeting aggregated peptides |
| RU2019102746A (ru) | 2016-07-14 | 2020-08-14 | Биоарктик Аб | Белок для транспорта в мозг |
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| MX2021000778A (es) | 2018-07-24 | 2021-03-31 | Eisai R&D Man Co Ltd | Metodos de tratamiento y prevencion de la enfermedad de alzheimer. |
| AU2020214796A1 (en) | 2019-01-30 | 2021-07-29 | Truebinding, Inc. | Anti-Gal3 antibodies and uses thereof |
| US20220251518A1 (en) * | 2019-07-08 | 2022-08-11 | Terumo Kabushik Kaisha | Hybridoma, method for making the same, monoclonal antibody, and method for making the same |
| WO2021055670A1 (en) | 2019-09-20 | 2021-03-25 | Avx Corporation | Somatic cell-based electrical biosensor |
| WO2021242776A2 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| RS66984B1 (sr) | 2020-06-26 | 2025-07-31 | Bioarctic Ab | Antitela koja vezuju alfa-sinuklein protofibril |
| EP4367516A1 (en) | 2021-07-09 | 2024-05-15 | Eisai R&D Management Co., Ltd. | Biomarkers for alzheimer's disease treatment |
| US20240352109A1 (en) | 2021-08-30 | 2024-10-24 | Eisai R&D Management Co., Ltd. | Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof |
| MX2024009492A (es) | 2022-02-02 | 2024-08-09 | Eisai R&D Man Co Ltd | Metodos de tratamiento mediante el uso del nivel de proteina tau fosforilada 181 (p-tau181). |
| PE20252307A1 (es) | 2022-12-22 | 2025-09-22 | Bioarctic Ab | Anticuerpo que se une a abetape3 |
| WO2025262228A1 (en) | 2024-06-20 | 2025-12-26 | Bioarctic Ab | Bispecific binding molecule |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5604102A (en) | 1992-04-15 | 1997-02-18 | Athena Neurosciences, Inc. | Methods of screening for β-amyloid peptide production inhibitors |
| ATE283285T1 (de) * | 1999-08-04 | 2004-12-15 | Univ Southern California | Globularer aufbau vom amyloid-beta- protein und deren verwendungen |
| EP1309341A2 (en) * | 2000-07-07 | 2003-05-14 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
| US7122374B1 (en) * | 2002-04-09 | 2006-10-17 | Takaomi Saido | Amyloid beta-protein 3(pE)-42 antibodies and uses thereof |
| CA2487528A1 (en) * | 2002-07-24 | 2004-02-12 | Innogenetics N.V. | Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation |
| KR100891620B1 (ko) * | 2004-04-13 | 2009-04-02 | 에프. 호프만-라 로슈 아게 | 항-ｐ-셀렉틴 항체 |
| GB0413726D0 (en) * | 2004-06-18 | 2004-07-21 | Lauras As | Compounds |
| SE0401601D0 (sv) * | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| BRPI0513959A (pt) * | 2004-07-30 | 2008-05-20 | Rinat Neuroscience Corp | anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos |
| RU2429244C2 (ru) * | 2006-03-23 | 2011-09-20 | Байоарктик Ньюросайенс Аб | Улучшенные селективные в отношении протофибрилл антитела и их применение |
| DK2207568T3 (en) * | 2007-11-16 | 2017-09-18 | Univ Rockefeller | ANTIBODIES SPECIFIC TO THE PROTOFIBRILE FORM OF BETA AMYLOID PROTEIN |
| PT2282758T (pt) * | 2008-04-29 | 2019-02-12 | Bioarctic Ab | Anticorpos e vacinas para uso em métodos terapêuticos e diagnósticos para perturbações relacionadas com a alfa-sinucleína |
-
2010
- 2010-06-29 PT PT107397010T patent/PT2448968T/pt unknown
- 2010-06-29 JP JP2012516964A patent/JP2012532094A/ja not_active Withdrawn
- 2010-06-29 CA CA2765602A patent/CA2765602C/en active Active
- 2010-06-29 HR HRP20210611TT patent/HRP20210611T1/hr unknown
- 2010-06-29 WO PCT/IB2010/052947 patent/WO2011001366A1/en not_active Ceased
- 2010-06-29 SM SM20210237T patent/SMT202100237T1/it unknown
- 2010-06-29 ES ES10739701T patent/ES2864049T3/es active Active
- 2010-06-29 PL PL10739701T patent/PL2448968T3/pl unknown
- 2010-06-29 HU HUE10739701A patent/HUE053949T2/hu unknown
- 2010-06-29 EP EP21153326.0A patent/EP3892633A1/en active Pending
- 2010-06-29 DK DK10739701.0T patent/DK2448968T3/da active
- 2010-06-29 SI SI201032068T patent/SI2448968T1/sl unknown
- 2010-06-29 US US13/379,523 patent/US20120100129A1/en not_active Abandoned
- 2010-06-29 EP EP10739701.0A patent/EP2448968B1/en active Active
- 2010-06-29 AU AU2010267640A patent/AU2010267640B2/en active Active
- 2010-06-29 LT LTEP10739701.0T patent/LT2448968T/lt unknown
-
2017
- 2017-04-19 JP JP2017083057A patent/JP6884025B2/ja active Active
-
2019
- 2019-08-01 JP JP2019142344A patent/JP2019218362A/ja active Pending
-
2021
- 2021-04-27 CY CY20211100361T patent/CY1124034T1/el unknown
-
2022
- 2022-12-15 US US18/066,998 patent/US20230295283A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20120100129A1 (en) | 2012-04-26 |
| JP6884025B2 (ja) | 2021-06-09 |
| HUE053949T2 (hu) | 2021-08-30 |
| CY1124034T1 (el) | 2022-05-27 |
| EP2448968B1 (en) | 2021-01-27 |
| CA2765602C (en) | 2021-05-25 |
| JP2019218362A (ja) | 2019-12-26 |
| JP2012532094A (ja) | 2012-12-13 |
| SI2448968T1 (sl) | 2021-07-30 |
| US20230295283A1 (en) | 2023-09-21 |
| JP2017197531A (ja) | 2017-11-02 |
| WO2011001366A1 (en) | 2011-01-06 |
| CA2765602A1 (en) | 2011-01-06 |
| EP2448968A1 (en) | 2012-05-09 |
| AU2010267640B2 (en) | 2015-03-05 |
| ES2864049T3 (es) | 2021-10-13 |
| LT2448968T (lt) | 2021-05-10 |
| PL2448968T3 (pl) | 2021-09-13 |
| SMT202100237T1 (it) | 2021-05-07 |
| EP3892633A1 (en) | 2021-10-13 |
| AU2010267640A1 (en) | 2012-01-19 |
| DK2448968T3 (da) | 2021-04-12 |
| PT2448968T (pt) | 2021-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210611T1 (hr) | Antitijela selektivna za amiloidne-beta-protofibrile/oligomere krnjih n-terminala | |
| Pellenard et al. | High-precision U-Pb zircon ages for explosive volcanism calibrating the NW European continental Autunian stratotype | |
| JP5926368B2 (ja) | アミロイドペプチドを測定するための抗体、キットおよび方法 | |
| AR078650A1 (es) | Anticuerpo de union a il-1 beta | |
| JP2009525758A5 (2) | ||
| Khalili-Shirazi et al. | PrP glycoforms are associated in a strain-specific ratio in native PrPSc | |
| DE69940364D1 (de) | Fab Fragmentbibliotheken und Verfahren für deren Verwendung | |
| JP2007527865A5 (2) | ||
| RU2015126533A (ru) | Анти-cd47 антитела и способы их применения | |
| WO2009136382A3 (en) | Antibodies to receptor of advanced glycation end products (rage) and uses thereof | |
| CL2007003771A1 (es) | Polinucleotido que codifica antigeno de n. meningitidis; vector y celula huesped que lo comprenden; polipeptido codificado; anticuerpo que se une al polipeptido; composicion que comprende el polinucleotido, vector, celula, polipeptido o anticuerpo an | |
| BRPI0607486B8 (pt) | anticorpo humanizado l243 contra hla-dr presente nas células hladr+,composição farmacêutica, kit e uso dos referidos anticorpos. | |
| WO2012009442A3 (en) | Anti-addl monoclonal antibody and uses thereof | |
| BRPI0410261B8 (pt) | anticorpo monoclonal que se liga especificamente ao probnp, métodos para detecção específica de probnp in vitro e para diagnóstico de insuficiência cardíaca in vitro, kit para medição de probnp, e linhagem celular de hibridoma mab 1.21.3 | |
| JP2012532094A5 (2) | ||
| PL1886140T3 (pl) | Testy immunologiczne i przeciwciała wobec hormonu anty-Müllerowskiego | |
| RU2017114626A (ru) | Антитело, связывающее линейный эпитоп человеческого р53, и его применение в диагностике | |
| WO2018049053A3 (en) | Peptides and uses thereof for diagnosing and treating myasthenia gravis | |
| Herrera et al. | Antivenomic characterization of two antivenoms against the venom of the taipan, Oxyuranus scutellatus, from Papua New Guinea and Australia | |
| ATE523523T1 (de) | Monoklonale anti minichomosome maintenance 2 protein antikörper und verfahren zu deren verwendung beim nachweis einer zervikalen erkrankung | |
| MX2023004212A (es) | Conjugados reactivos. | |
| Rasmussen et al. | A novel antihuman C3d monoclonal antibody with specificity to the C3d complement split product | |
| ATE526345T1 (de) | Antikörper und ihre verwendung bei der behandlung,vorbeugung und diagnose einer mit sod1-anomalien assoziierten krankheit | |
| US20130177567A1 (en) | Novel c3c epitope, antibodies binding thereto, and use thereof | |
| US20140241987A1 (en) | Alpha-synuclein antibodies and uses thereof |